Accelerate Diagnostics and Bruker have signed a collaboration and quality agreement to validate the use of the Arc system with the MALDI Biotyper system.

The partnership aims to verify the use of Accelerate’s Arc system with Bruker’s MALDI Biotyper sirius instruments and Sepsityper software for registration in both Europe, the Middle East and Africa, and US markets.

Created for use in clinical laboratories, the Arc system streamlines workflow with an easy load-and-go process, automating the preparation of positive blood culture samples for downstream microbial identification using the MALDI Biotyper system.

The system enables processing samples as needed, eliminating the requirement for overnight culture incubation, and thereby minimising the time needed for identification results.

Laboratories can utilise the Bruker MALDI-Biotyper identification library alongside quick antibiotic susceptibility results from the Accelerate Pheno system.

Additionally, they can integrate it with the Accelerate WAVE system, currently in development and scheduled for release.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using Bruker’s Biotyper system alongside the Arc system has the potential to decrease the chances of cross-reactivity and false positives associated with fast molecular tests.

Accelerate president and CEO Jack Phillips said: “When you think of the extreme demand that labs are under today, the Arc system is a fast and inexpensive diagnostic tool which frees up technician hands and lab budgets to deliver actionable results in the race against sepsis.

“We look forward to working with Bruker, the recognised leader in mass spectrometry-based microbial identification, to bring this much-needed solution to laboratories.”

In March last year, Accelerate introduced the Arc system for quick and accurate microbial identification of positive blood cultures.